Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

Leukemia

Volumn 14, Issue 5, 2000, Pages 841-844

  Tassone, P ^a   Forciniti, S ^a   Galea, E ^a   Morrone, G ^a   Turco, M C ^a   Martinelli, V ^b   Tagliaferri, P ^a   Venuta, S ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bisphosphonates; Dexamethasone; Multiple myeloma; Myeloma cell lines; Zoledronate

Indexed keywords

DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE ATROPHY; CELL LINE; CONTROLLED STUDY; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0034055664     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401770     Document Type: Article

References (27)

1. Mundy GR, Bertoline DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13: 291-299.
2. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol 1995; 90: 721-724.
3. Stashenko P, Dewhirst FE, Peros WJ, Ago JM. Synergistic interactions between interleukin-1, tumor necrosis factor and lymphotoxin in bone resorption. J Immunol 1987; 138: 1464-1468.
4. Fleisch H. Bisphophonates: pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 1991; 42: 919-944.
5. Coleman RE, Purohit OP. Osteoclast inhibitor for the treatment of bone metatases. Cancer Treat Rev 1993; 19: 79-103.
6. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997; 80: 1652-1660.
7. Shipman CM, Rogers MJ, Apperley JF, Russel RGG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 1997; 98: 665-672.
8. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 220-229.
9. Dhodapkar MV, Singh J, Metha J, Fassas A, Desikan KR, Perlman M, Munshi NC. Anti-myeloma activity of pamidronate in vivo. Br J Haematol 1998; 103: 530-532.
10. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Badoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ. Heffernan M, Seaman J, Knight D. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593-602.
11. McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100: 317-325.
12. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-751.
13. Zhang X, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Bairon JM, Bataille R, Klein B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654-3663.
14. Carbonari M, Cibati M, Fiorilli M. Measurement of apoptotic cells in peripheral blood. Cytometry 1995; 22: 161-167.
15. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi CA. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139: 271-279.
16. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795-808.
17. Ogreid D, Ekanger R, Suva RH, Miller JP, Sturm P, Corbin JD, Doskeland SO. Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination. Principles for optimizing the isozyme specificity of analog combinations. Eur J Biochem 1985; 150: 219-227.
18. Shipman CM, Croucher PI, Russel GR, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294-5297.
19. Gibbs JB, Olif A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997; 37: 143-166.
20. Dallas SL, Garret IR, Bonewald LF, Gilles J, Boyce BF, Radl J, Mundy GR. Evidence for a vicious cycle between myeloma growth in bone and osteoclastic bone resorption. Blood 1994; 844: 176a.
21. Barille S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86: 685-691.
22. GR, Raisz LG, Cooper RA, Schechter GP, Salmon S. Evidence for the secretion of an osteoclast stimulating factor in myeloma. New Engl J Med 1974; 291: 1041-1046.
23. Savage AD, Belson DJ, Vescio RA, Lichtenstein AK, Berenson JR. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 1996; 88: 105a.
24. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863-872.
25. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-3070.
26. Grigorieva I, Thomas H, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Haematol 1998; 26: 597-603.
27. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-2105.